Moderna has begun the first human trial of an mRNA vaccine targeting Bundibugyo ebolavirus, the Ebola species responsible for an outbreak in the Democratic Republic of the Congo for which no approved vaccine exists.
The first participants received the investigational vaccine, mRNA-1469, in early August at three sites in Canada after Health Canada authorized the study. The trial aims to enroll about 80 healthy adults and will assess safety, tolerability, and whether the vaccine generates an immune response.
